Obesity evidence dossier
MariTide (maridebart cafraglutide)
The main question is not only potency, but whether less-frequent dosing can improve long-term persistence. Phase 3 72-week efficacy and maintenance data are the next key read.
Total weight loss
16.2%
MariTide Phase 2, Cohort A · highest reported arm · week 52 · Includes treatment stops
Placebo-adjusted
13.7%
Difference from placebo in the same study when reported.
Study context
GLP-1 receptor agonist / GIP receptor antagonist conjugate/Adults with obesity or overweight, without diabetes/465 participants across the study/52-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
MariTide Phase 2, Cohort A · highest reported arm · 52 weeks
Adults with obesity or overweight, without diabetes. 465 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.
- Average weight loss
- 16.2%
- Placebo group
- 2.5% loss
- Beyond placebo
- 13.7 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 66.8 total-loss points + 30% × 66.3 beyond-placebo points = 67/100, rounded. Conversion scales
Alternative analysis assuming continued treatment: 19.9% total loss. This is not the result used for the headline score. Alternative analysis source ↗
Amgen, Phase 2 results ↗Phase 2 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
MariTide Phase 2, Cohort A: Includes treatment stops.
Diabetes data
Separate Phase 2 diabetes cohorts showed less weight loss than the non-diabetic obesity cohort.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Gastrointestinal adverse events, especially nausea and vomiting during escalation, are the main tolerability watch item.
Main cautions
Not approved; Phase 3 needs to clarify dose spacing, discontinuations, maintenance, and safety with longer exposure.
Upcoming catalyst
What to watch next
No verified readout dateExpected
Does less-frequent dosing preserve substantial weight loss with manageable discontinuation?
Watch for: MARITIME Phase 3 results and treatment discontinuations. Trial completion dates should not be presented as promised data-release dates.
Source: Amgen, Q2 2026 resultsLinked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06987695
Phase 3
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Amgen
Non-diabetic obesity
Dec 17, 2025
NCT07037459
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
Non-diabetic obesity
Apr 2, 2026
NCT07037433
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
Non-diabetic obesity
Mar 27, 2026
NCT07441252
Phase 2
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Amgen
Non-diabetic obesity
Apr 2, 2026
NCT06352892
Phase 1
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
Amgen
Non-diabetic obesity
Jan 8, 2026
NCT07310563
Phase 1
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
Amgen
Non-diabetic obesity
Dec 30, 2025
NCT04478708
Phase 1
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Amgen
Non-diabetic obesity
Dec 10, 2025
NCT06976372
Phase 1
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
Amgen
Non-diabetic obesity
Oct 8, 2025
NCT06858878
Phase 3
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen
Type 2 diabetes / obesity
Dec 31, 2025
NCT06858839
Phase 3
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen
Type 2 diabetes / obesity
Oct 20, 2025
NCT05669599
Phase 2
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Amgen
Type 2 diabetes / obesity
Jan 20, 2026